CMO Draft Guidance Overly Prescriptive, Out Of Touch – Industry
This article was originally published in The Rose Sheet
Executive Summary
PCPC and other trade groups, as well as firms including Pfizer and Merck, say FDA’s draft guidance on quality agreements between drug contract manufacturers and marketers goes into excessive detail and is inconsistent with actual business arrangements common in the industry.
You may also be interested in...
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.
Some Topical Analgesics Draw Outside US FDA’s Lines For Formulations And Indications
FDA warns six businesses found selling directly to consumers topical formulations containing lidocaine outside the 0.5% to 4% concentration range allowed under OTC monographs for topical analgesics